DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Cardiovascular Function in Acute Leukemia

Completed

Conditions: Leukemia, Lymphoid, Acute
Cardiotoxicity
Leukemia, Myeloid, Acute

Interventions: Other: observation only

First Posted Date: 2018-11-30

Last Posted Date: 2024-10-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 84

Registration Number: NCT03760237

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Phase 1

Withdrawn

Conditions: Pancreas Cancer

Interventions: Drug: Entinostat
Drug: FOLFOX regimen

First Posted Date: 2018-11-30

Last Posted Date: 2021-01-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03760614

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Phase 1

Recruiting

Conditions: Mesotheliomas Pleural

Interventions: Drug: Pembrolizumab
Procedure: Indocyanine Green (ICG) Image-Guided Surgery
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2018-11-30

Last Posted Date: 2025-01-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT03760575

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Pembrolizumab
Procedure: Wide Excision and Sentinel Lymph Node (SLN) Biopsy

First Posted Date: 2018-11-29

Last Posted Date: 2025-02-11

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 63

Registration Number: NCT03757689

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Yoga for Solid Tumor

Not Applicable

Withdrawn

Conditions: Solid Tumor, Adult

Interventions: Behavioral: Yoga

First Posted Date: 2018-11-02

Last Posted Date: 2021-04-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03728205

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Not Applicable

Active, not recruiting

Conditions: Human Papilloma Virus
Squamous Cell Carcinoma
Oropharyngeal Cancer

Interventions: Radiation: Radiation Therapy (IMRT or IMPT)

First Posted Date: 2018-11-02

Last Posted Date: 2025-02-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 150

Registration Number: NCT03729518

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Young Adults and Low Nicotine Cigarettes

Not Applicable

Withdrawn

Conditions: Smoking

Interventions: Other: Nicotine content

First Posted Date: 2018-10-09

Last Posted Date: 2024-10-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03699865

Locations: 🇺🇸
Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Phase 2

Terminated

Conditions: Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-10-03

Last Posted Date: 2022-10-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 11

Registration Number: NCT03693846

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients with BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer
Locally Advanced Breast Cancer
Advanced Breast Cancer
BRCA2 Mutation
BRCA1 Mutation

Interventions: Drug: Palbociclib
Drug: Olaparib
Drug: Fulvestrant

First Posted Date: 2018-09-26

Last Posted Date: 2025-03-03

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 54

Registration Number: NCT03685331

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Recruiting

Conditions: Leukemia, Acute
MDS

Interventions: Procedure: Bone Marrow or Peripheral Blood Graft (BMT)
Other: Cancer-directed Therapy or Best Supportive Care
Diagnostic Test: Frailty Assessment

First Posted Date: 2018-09-21

Last Posted Date: 2024-07-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT03680677

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy